Zero Shot Podcast DEMO

Nicket Uttarwar
  • 0.0 (0)
  • Entrepreneurship
  • Updated Biweekly

Zero Shot Podcast DEMO is a long-form business interview podcast. Each episode sits with founders, operators, and builders for unhurried conversations about entrepreneurship, product, capital, and the hard calls that shape companies.

Episodes

  1. 3h ago

    From Stevia Setbacks to Max Protein

    Naturell’s founder traces a route from a village near Nagpur to a consumer-brand ambition: building healthier snacks while improving farmer livelihoods. His early plan was stevia, a crop he believed could offer farmers a higher-income alternative. When the tabletop-sweetener bet stalled, Naturell had to learn what the market would actually recognise. He recounts the costly lessons that followed: a calcium bar priced for the wrong shelves, children mistaking nutrition for chocolate, and a gradual shift away from vague health claims toward visible functional benefits. That shift led to Max Protein, a 20-gram bar designed around what consumers were already seeking. The conversation also follows Naturell’s expansion into millet-based protein chips, cookies, granola, peanut butter and plant protein, and examines the goal of turning Max Protein into a broader healthy-snacking platform. With the business at roughly ₹160–170 crore, he explains why a partnership with Zyder's Wellness is intended to help pursue a ₹1,000-crore brand.

    From Stevia Setbacks to Max Protein

  2. 7h ago

    Granola’s Fight to Stay Human

    Granola began with a deceptively modest question: what if meeting notes could be more useful without taking over the meeting? In this episode, co-founder Sam Stevenson traces how a familiar-looking notes app came to listen across Zoom and in-person conversations, then build on the signals a user chooses to capture. He explains why the company’s bigger ambition—to become a context-aware work companion—depends on resisting the usual AI-product temptations. That same restraint shaped Granola’s rebrand: the team wanted energy and honesty about the mess of work, not a glossy corporate identity designed for procurement. Stevenson also revisits the uncertain road from independent designer to co-founder, including a janky early prototype and six months spent pursuing real-time AI notes before deciding that the better experience happened after the meeting. As Granola grows in London, he considers the harder questions still ahead: how to preserve candid private notes while enabling collaboration, how to hire for empathy, and how habit, simplicity and trust might matter more than chasing every new model.

    Granola’s Fight to Stay Human

  3. 2d ago

    Precision Oncology V3

    Mohan Uttarwar argues that combining circulating tumour-cell analysis, multi-omics, and AI could make precision oncology

    Precision Oncology V3

  4. 2d ago

    Hunting Living Tumour Cells in a Blood Draw V2

    Attribution https://www.youtube.com/watch?v=xrLowO63fqU Cancer monitoring often relies on tissue samples, DNA fragments and scans that can take months to show whether a treatment is working. In this episode, OneCell.ai’s Mohan Uttarwar describes the company’s proposed “cell biopsy” approach: capturing rare circulating tumor cells from blood, then reading them alongside circulating tumor DNA. He explains why intact cells may add context that DNA fragments alone cannot provide, and how single-cell multi-omics, morphology imaging and AI are intended to turn complex signals into clinically actionable interpretation. The conversation follows OneCell.ai’s OncoInsight assay, which pairs a 1,080-gene ctDNA panel with circulating-tumor-cell analysis rather than treating either source as sufficient on its own. The stakes extend from biomarker-led trial enrolment to detecting response or resistance sooner than imaging-based assessment. Uttarwar also outlines the less glamorous work required for a diagnostic to matter: independent validation, laboratory and regulatory pathways, reimbursement and commercial partnerships. The episode closes on the central question facing AI-enabled cancer diagnostics: can a richer blood-based picture of a changing tumor earn the evidence, access and clinical trust needed to improve precision oncology?

    Hunting Living Tumour Cells in a Blood Draw V2

  5. 3d ago

    Listening for Cancer’s Signal in a Blood Draw

    Podcast Attribution https://www.youtube.com/watch?v=xrLowO63fqU What if a blood draw could reveal cancer signals that imaging and single samples may not fully capture? Mohan Uttarwar explains why precision oncology is moving beyond the tissue biopsy and beyond ctDNA alone. He traces the difference between fragments of tumour DNA shed by dying cells and rare intact circulating tumour cells—cells that may offer a living view of a tumour’s evolution. Uttarwar describes OneCell.ai’s “cell biopsy” approach: capturing those cells, then combining imaging with DNA, RNA and protein analysis. AI, in this account, helps connect that high-dimensional picture to questions clinicians and trial teams face: where a tumour may have come from, whether treatment is working, and when resistance may be emerging. The conversation examines OncoInsight’s combined ctDNA and CTC workflow, the role of molecular patient selection in clinical studies, and the ambition to see response or resistance in weeks rather than months. Uttarwar also separates reported analytical-validation progress and regulatory pathways from a longer-term goal: earlier, less invasive monitoring for recurrence. It is a conversation about promise, proof and the careful work required before a richer blood signal can change care.

    Listening for Cancer’s Signal in a Blood Draw
  • 5 Episodes

About

Zero Shot Podcast DEMO is a long-form business interview podcast. Each episode sits with founders, operators, and builders for unhurried conversations about entrepreneurship, product, capital, and the hard calls that shape companies.

Information